Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF MAY 05, 2018 FBO #6007
MODIFICATION

65 -- Antidote Treatment Nerve Agent Auto-Injector

Notice Date
5/3/2018
 
Notice Type
Modification/Amendment
 
NAICS
325412 — Pharmaceutical Preparation Manufacturing
 
Contracting Office
Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Clothing & Textiles, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
 
ZIP Code
19111-5096
 
Solicitation Number
SPE2DP-18-R-0200
 
Archive Date
5/26/2018
 
Point of Contact
Danielle Delaney, Phone: 215-737-2998
 
E-Mail Address
Danielle.Delaney@dla.mil
(Danielle.Delaney@dla.mil)
 
Small Business Set-Aside
N/A
 
Description
The Defense Logistics Agency Troop Support is seeking sources capable of providing the Antidote Treatment Nerve Agent Auto-Injector (ATNAA). DLA Troop Support is contemplating awarding a requirements contract with a one-year base and six one year options for the ATNAA. The estimated average annual quantity to be ordered is 1.2 million units. However, the quantity may increase or decrease as the Services requirements change. The ATNAA shall be licensed by the Food and Drug Administration (FDA). Each auto-injector shall deliver 2.1 mg of atropine and 600mg of pralidoxime chloride in separate chambers, and be suitable for intramuscular administration. Must have FDA approval to sell the ATNAA before award of the contract. If your firm currently manufactures or distributes the ATNAA, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the ATNAA or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Your response to this RFI may be submitted electronically in pdf format and emailed to danielle.delaney@dla.mil by May 26, 2018.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-C/SPE2DP-18-R-0200/listing.html)
 
Record
SN04909887-W 20180505/180503230818-35a913823d72c4e976fc8bc06817c931 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.